¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.
OBJECTIVE
Tumour angiogenesis is an independent and strong prognostic factor in early breast carcinoma. We performed this study to investigate the ability of (18)F-FDG to detect angiogenesis in early breast carcinoma using PET/CT.


METHODS
Twenty consecutive patients with early (T1-T2) breast carcinoma were recruited prospectively for 18F-FDG PET/CT. The PET/CT data were used to calculate whole tumour maximum standardized uptake value (SUV(max)) and mean standardized uptake value (SUV(mean)). All patients underwent subsequent surgery without prior chemotherapy or radiotherapy. The excised tumour underwent immunohistochemistry for vascular endothelial growth factor (VEGF), CD105 and glucose transporter protein 1 (GLUT1).


RESULTS
The SUV(max) showed the following correlation with tumour histology: CD105: r = 0.60, p = 0.005; GLUT1: r = 0.21, p = 0.373; VEGF: r = -0.16, p = 0.496. The SUV(mean) showed the following correlation with tumour histology: CD105: r = 0.65, p = 0.002; GLUT1: r = 0.34, p = 0.144; VEGF: r = -0.18, p = 0.443


CONCLUSIONS
(18)F-FDG uptake is highly significantly associated with angiogenesis as measured by the immunohistochemistry with CD105 for new vessel formation. Given that tumour angiogenesis is an important prognostic indicator and a predictor of treatment response, (18)F-FDG PET may have a role in the management of primary breast cancer patients even in early-stage disease.
Groves
Ashley M
AM
Institute of Nuclear Medicine, University College London, London, UK. drashleygroves@hotmail.com
Shastry
Manu
M
Rodriguez-Justo
Manuel
M
Malhotra
Anmol
A
Endozo
Raymondo
R
Davidson
Timothy
T
Kelleher
Tina
T
Miles
Kenneth A
KA
Ell
Peter J
PJ
Keshtgar
Mohammed R
MR
D000368:Aged; D001692:Biological Transport; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006801:Humans; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging* / Q000378:metabolism*; D049268:Positron-Emission Tomography
D014408:Biomarkers, Tumor; D019788:Fluorodeoxyglucose F18